<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main"></title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">715E1C1C7993497877A5E117B02DE524</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-05-22T20:48+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">unknown</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=1, consolidateHeader=1, consolidateFunders=0, includeRawAffiliations=false, includeRawCitations=true, includeRawCopyrights=false, generateTeiIds=false, generateTeiCoordinates=[], flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experiment title:</head><p>Exafs Study of Pt anticancer drugs in cells and tissues.</p><p>Experiment number: MD 425 Beamline: Date of experiment: from: 08.04.2009 to: 12.04.2009 Date of report: Shifts: Local contact(s): Sergey Nikitenko Received at ESRF: Names and affiliations of applicants (* indicates experimentalists): Annette Rompel a* Ana Mijovilovich b* Alina Nemirovski c* Lily Katz c* a) University of Vienna, Austria b) University of Utrecht, The Netherlands c) Hebrew University of Jerusalem, Israel Report:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Aims of the experiment and scientific background</head><p>Cisplatin is among the most important chemotherapeutic agents ever developed. It is a critical component of therapeutic regimens in a broad range of malignancies <ref type="bibr" target="#b0">[1]</ref>. However, more than three decades after its clinical introduction, the exact mechanism of cisplatin action on tumor cells is not fully understood. It is commonly accepted that cisplatin kills the cancer cell by binding covalently and essentially irreversibly to the nuclear DNA. The binding occurs in the major groove of the DNA where the two cis-chloride ligands are replaced by two N7 atoms of two adjacent guanines on the same strand of the DNA. This distortion of the DNA triggers cellular responses that in favorable cases end in the induction of apoptosis <ref type="bibr" target="#b1">[2]</ref>. It is noteworthy that only approximately 1% of the cellular platinum ends up bound to the nuclear DNA. Yet, nearly 99% of the research efforts have been directed to studying all aspects of Pt-DNA lesions. Pt-DNA adducts formed in the different cancer cells are expected to be the same, but why is cisplatin very effective only against some types of cancer (testicular, ovarian). It seems, the Pt-non-DNA adducts are responsible for that. Very little is known about these interactions and most of the information pertaining to the mode of action is derived from simplistic aqueous models. Based on model studies, and basic inorganic chemistry, it is expected that most of the cellular cisplatin will bind to sulfur containing ligands and especially to glutathione (GSH), a thiol containing tripeptide that exists in mM concentrations. There is one report claiming that 60% of the cellular platinum is bound to GSH <ref type="bibr" target="#b2">[3]</ref>. Yet, in recent [ 1 H, 15 N] 2D-NMR studies that we conducted by labeling cisplatin with 15 N ammine ligands, and monitoring the interactions with aqueous extracts of cancer cells, contrary to expectations, we were unable to detect any sulfur binding to cisplatin. This might be due to certain limitation of NMR spectroscopy, which would make it impossible to observe signals of cisplatin bound to large biopolymers. The interaction of cellular sulfur with Pt anticancer agents is believed to play a major role, and could serve to either inactivate the Pt drugs (by binding to thiols) or to activate drugs such as carboplatin (by binding to thioether). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>EXAFS L 3 Pt-edge were collected on all samples at BM26A beamline (ESRF). Samples of cells, cell extracts and mice treated tumors were measured. Samples were placed in Kapton sealed holders and kept frozen at all times. Measurements were performed at 15 K using a cryostat and data was collected using a multielement Ge solid-state detector. The April 2009 beamtime has been dedicated on two projects: 1) In March 2008 we monitored the cellular reduction of Pt(IV) complexes in mouse cancer cells, the cells were treated with the Pt(IV) complexes: ct-[Pt(NH 3 ) 2 (OH) 2 (oxal)] and ct-[Pt(NH 3 ) 2 (OAc) 2 (oxal)] at a concentration of 100 mM. In generell a reduction of Pt(IV) compounds is seen over time.</p><p>2) Hall et. al. <ref type="bibr" target="#b3">[4]</ref> showed that the XANES spectra of Pt(IV) and Pt(II) complexes have absorption profiles that differ primarily in the height of their edges, with the former displaying a much higher edge. The authors also showed that the ratio of a/b (Fig. <ref type="figure" target="#fig_1">1 right</ref>) is characteristic of the oxidation state and that this ratio correlated linearly with percentage of each of the oxidation states in mixtures. We decided to employ XANES to check whether the intermediates in the reduction of ctc-[PtCl 2 ( 13 CH 3 CO 2 ) 2 ( 15 NH 3 )(NBA)] (NBA = n-butylamine) by ascorbate, peak 2 in fig. <ref type="figure" target="#fig_1">1</ref> left, is a Pt(II) or Pt(IV) complex. The reduction was monitored by [ 1 H, 13 C] HSQC and was allowed to proceed until the peak of the Pt(IV) starting material comprised approximately 10-15 % of the total HSQC signal. At this point the strongest peak in the spectrum was that of the intermediate (peak 2 fig. <ref type="figure" target="#fig_1">1</ref> left). The sample was quickly frozen in liquid nitrogen and lyophilized, and a boronitride pellet was analysed by XANES. The XANES spectra showed that approximately 77 % of the platinum is in the form of Pt(II) and 23 % is in the form of Pt(IV). These results support the NMR data that suggest that the intermediate is a Pt(II) complex <ref type="bibr" target="#b10">[11]</ref>.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 1</head><label>1</label><figDesc>Fig. 1 left: The [ 1 H, 13 C] HSQC spectrum of the reduction of ctc-[PtCl 2 ( 13 CH 3 CO 2 ) 2 ( 15 NH 3 )(NBA)] by 10 eqiv. of sodium ascorbate in phosphate buffer at 37 ÂºC showing around 17% starting material and primarily the Pt intermediate.</figDesc><graphic coords="3,48.48,361.50,489.38,211.80" type="bitmap" /></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Current Status of Platinum-Based Antitumor Drugs</title>
		<author>
			<persName><forename type="first">Ernest</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Christen</forename><forename type="middle">M</forename><surname>Giandomenico</surname></persName>
		</author>
		<idno type="DOI">10.1021/cr980420v</idno>
	</analytic>
	<monogr>
		<title level="j">Chemical Reviews</title>
		<title level="j" type="abbrev">Chem. Rev.</title>
		<idno type="ISSN">0009-2665</idno>
		<idno type="ISSNe">1520-6890</idno>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2451" to="2466" />
			<date type="published" when="1999-08-17">1999</date>
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong, E., Giandomenico, C.M. Chem. Rev. 1999. 99 (9) 2451-2466.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cellular processing of platinum anticancer drugs</title>
		<author>
			<persName><forename type="first">Dong</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Stephen</forename><forename type="middle">J</forename><surname>Lippard</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrd1691</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Drug Discovery</title>
		<title level="j" type="abbrev">Nat Rev Drug Discov</title>
		<idno type="ISSN">1474-1776</idno>
		<idno type="ISSNe">1474-1784</idno>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="307" to="320" />
			<date type="published" when="2005-03-24">2005</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang, D., Lippard, S.J. Nature Reviews Drug Discovery. 2005, 4, 307-320.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance.</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ali-Osman</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0021-9258(20)80702-9</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">Journal of Biological Chemistry</title>
		<idno type="ISSN">0021-9258</idno>
		<imprint>
			<biblScope unit="volume">268</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="20116" to="20125" />
			<date type="published" when="1993-09">1993</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Ishikawa, T., Ali-Osman, F. J. Biol. Chem. 1993. 268 (27), 20116-20125.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">XANES Determination of the Platinum Oxidation State Distribution in Cancer Cells Treated with Platinum(IV) Anticancer Agents</title>
		<author>
			<persName><forename type="first">Matthew</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garry</forename><forename type="middle">J</forename><surname>Foran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mei</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Philip</forename><forename type="middle">J</forename><surname>Beale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Trevor</forename><forename type="middle">W</forename><surname>Hambley</surname></persName>
		</author>
		<idno type="DOI">10.1021/ja0354770</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of the American Chemical Society</title>
		<title level="j" type="abbrev">J. Am. Chem. Soc.</title>
		<idno type="ISSN">0002-7863</idno>
		<idno type="ISSNe">1520-5126</idno>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="7524" to="7525" />
			<date type="published" when="2003-05-30">2003</date>
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Hall, M.D., Foran, G.J., Zhang,M., Beale, P.J.,and Hambley, T.W. JACS. 2003, 125, 7524-7525.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Rompel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Meyer-Klauke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mijovilovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Eichinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jakupec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Keppler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Inorg. Chem</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>Suppl. 1, S15</note>
	<note type="raw_reference">Rompel, A., Meyer, T., Meyer-Klauke, W., Mijovilovich, A., Eichinger, R., Jakupec, M., Keppler, B.K. J. Biol. Inorg. Chem. 2007. 12, Suppl. 1, S15.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)]</title>
		<author>
			<persName><forename type="first">Viktor</forename><surname>Brabec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Petros</forename><surname>Christofis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Martina</forename><surname>SlÃ¡movÃ¡</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hana</forename><surname>KostrhunovÃ¡</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Olga</forename><surname>NovÃ¡kovÃ¡</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yousef</forename><surname>Najajreh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dan</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jana</forename><surname>KaÅ¡pÃ¡rkovÃ¡</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bcp.2007.03.003</idno>
	</analytic>
	<monogr>
		<title level="j">Biochemical Pharmacology</title>
		<title level="j" type="abbrev">Biochemical Pharmacology</title>
		<idno type="ISSN">0006-2952</idno>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1887" to="1900" />
			<date type="published" when="2007-06">2007</date>
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Brabec, V.; Christofis, P.; Slamova, M.; Kostrhunova, H.; Novakova, O.; Najajreh, Y.; Gibson, D.; Kagparkova, J. Biochemical Pharmacology 2007, 73, (12), 1887-1900.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Cationic Nonsymmetric Transplatinum Complexes with Piperidinopiperidine Ligands. Preparation, Characterization, in Vitro Cytotoxicity, in Vivo Toxicity, and Anticancer Efficacy Studies</title>
		<author>
			<persName><forename type="first">Yousef</forename><surname>Najajreh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elena</forename><surname>Khazanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Seba</forename><surname>Jawbry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yael</forename><surname>Ardeli-Tzaraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jose</forename><forename type="middle">Manuel</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jana</forename><surname>Kasparkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Viktor</forename><surname>Brabec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yechezkel</forename><surname>Barenholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dan</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1021/jm060237r</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<title level="j" type="abbrev">J. Med. Chem.</title>
		<idno type="ISSN">0022-2623</idno>
		<idno type="ISSNe">1520-4804</idno>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="4665" to="4673" />
			<date type="published" when="2006-06-28">2006</date>
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Najajreh, Y.; Khazanov, E.; Jawbry, S.; Ardeli-Tzaraf, Y.; Perez, J. M.; Kasparkova, J.; Brabec, V.; Barenholz, Y.; Gibson, D. Journal of Medicinal Chemistry 2006, 49, (15), 4665-4673.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Interactions of Platinum Complexes Containing Cationic, Bicyclic, Nonplanar Piperidinopiperidine Ligands with Biological Nucleophiles</title>
		<author>
			<persName><forename type="first">Yousef</forename><surname>Najajreh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yael</forename><surname>Ardeli-Tzaraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jana</forename><surname>Kasparkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pavla</forename><surname>Heringova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dmitri</forename><surname>Prilutski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Liliana</forename><surname>Balter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Seba</forename><surname>Jawbry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Elena</forename><surname>Khazanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jose</forename><forename type="middle">Manuel</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yechezkel</forename><surname>Barenholz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Viktor</forename><surname>Brabec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dan</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1021/jm060238j</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Medicinal Chemistry</title>
		<title level="j" type="abbrev">J. Med. Chem.</title>
		<idno type="ISSN">0022-2623</idno>
		<idno type="ISSNe">1520-4804</idno>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="4674" to="4683" />
			<date type="published" when="2006-06-28">2006</date>
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Najajreh, Y.; Ardeli-Tzaraf, Y.; Kasparkova, J.; Heringova, P.; Prilutski, D.; Balter, L.; Jawbry, S.; Khazanov, E.; Perez, J. M.; Barenholz, Y.; Brabec, V.; Gibson, D. Journal of Medicinal Chemistry 2006, 49, (15), 4674-4683.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR</title>
		<author>
			<persName><forename type="first">Dan</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yonit</forename><surname>Kasherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dina</forename><surname>Kowarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Inna</forename><surname>Freikman</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00775-005-0064-7</idno>
	</analytic>
	<monogr>
		<title level="j">JBIC Journal of Biological Inorganic Chemistry</title>
		<title level="j" type="abbrev">J Biol Inorg Chem</title>
		<idno type="ISSN">0949-8257</idno>
		<idno type="ISSNe">1432-1327</idno>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="179" to="188" />
			<date type="published" when="2006">2006</date>
			<publisher>Springer Science and Business Media LLC</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Gibson, D.; Kasherman, Y.; Kowarski, D.; Freikman, I. Journal of Biological Inorganic Chemistry 2006, 11..</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Mass spectrometric studies of the formation and reactivity of &lt;i&gt;trans&lt;/i&gt;â[PtCl&lt;sub&gt;2&lt;/sub&gt;(Am)(piperidinopiperidine)] Â· HCl complexes with ubiquitin</title>
		<author>
			<persName><forename type="first">Liliana</forename><surname>Balter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dan</forename><surname>Gibson</surname></persName>
		</author>
		<idno type="DOI">10.1002/rcm.2244</idno>
	</analytic>
	<monogr>
		<title level="j">Rapid Communications in Mass Spectrometry</title>
		<title level="j" type="abbrev">Rapid Comm Mass Spectrometry</title>
		<idno type="ISSN">0951-4198</idno>
		<idno type="ISSNe">1097-0231</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="3666" to="3672" />
			<date type="published" when="2005-11-14">2005</date>
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Balter, L.; Gibson, D. Rapid Communications in Mass Spectrometry 2005, 19, (24), 3666-3672.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">New reduction pathways for &lt;i&gt;ctc&lt;/i&gt;-[PtCl&lt;sub&gt;2&lt;/sub&gt;(CH&lt;sub&gt;3&lt;/sub&gt;CO&lt;sub&gt;2&lt;/sub&gt;)&lt;sub&gt;2&lt;/sub&gt;(NH&lt;sub&gt;3&lt;/sub&gt;)(Am)] anticancer prodrugs</title>
		<author>
			<persName><forename type="first">Alina</forename><surname>Nemirovski</surname></persName>
			<affiliation>
				<orgName type="collaboration">D. submit. to Angew. Chem</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Inbal</forename><surname>Vinograd</surname></persName>
			<affiliation>
				<orgName type="collaboration">D. submit. to Angew. Chem</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Khuloud</forename><surname>Takrouri</surname></persName>
			<affiliation>
				<orgName type="collaboration">D. submit. to Angew. Chem</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Ana</forename><surname>Mijovilovich</surname></persName>
			<affiliation>
				<orgName type="collaboration">D. submit. to Angew. Chem</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Annette</forename><surname>Rompel</surname></persName>
			<affiliation>
				<orgName type="collaboration">D. submit. to Angew. Chem</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">Dan</forename><surname>Gibson</surname></persName>
			<affiliation>
				<orgName type="collaboration">D. submit. to Angew. Chem</orgName>
			</affiliation>
		</author>
		<idno type="DOI">10.1039/b925721g</idno>
	</analytic>
	<monogr>
		<title level="j">Chemical Communications</title>
		<title level="j" type="abbrev">Chem. Commun.</title>
		<idno type="ISSN">1359-7345</idno>
		<idno type="ISSNe">1364-548X</idno>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1842" to="1844" />
			<date type="published" when="2009">2009</date>
			<publisher>Royal Society of Chemistry (RSC)</publisher>
		</imprint>
	</monogr>
	<note type="raw_reference">Nemirovski, A.; Vinograd, I.; Takrouri, K.; Mijovilovich, A.; Rompel, A.; Gibson, D. submit. to Angew. Chem. 2009.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
